Get started
Author

M. L. Wang

Observed name: M.L. Wang
OpenAlex ID: A5086537029
Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes
2015 · C.Y. Cheah, D. Chihara, et al. · Annals of Oncology · 177
Breakthrough therapies in B-cell non-Hodgkin lymphoma
2016 · C.Y. Cheah, N.H. Fowler, et al. · Annals of Oncology · 39
PDF
Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era
2016 · C.Y. Cheah, D. Chihara, et al. · Annals of Oncology · 28
Acalabrutinib With Rituximab as First‐line Therapy for Older Patients With Mantle Cell Lymphoma—a Phase Ii Clinical Trial
2023 · P. Jain, C. y. Ok, et al. · Hematological Oncology · 11
PDF
IBRUTINIB‐RITUXIMAB FOLLOWED BY REDUCED CHEMO‐IMMUNOTHERAPY CONSOLIDATION IN YOUNG, NEWLY DIAGNOSED MANTLE CELL LYMPHOMA PATIENTS: a WINDOW OF OPPORTUNITY TO REDUCE CHEMO
2017 · M.L. Wang, H. Lee, et al. · Hematological Oncology · 9
PDF
Zilovertamab vedotin (MK‐2140) in relapsed or refractory (R/R) non‐Hodgkin lymphoma (NHL): 14‐month follow‐up of the phase 1 waveLINE‐001 study
2023 · M. L. Wang, M. Mei, et al. · Hematological Oncology · 6
PDF
Ibrutinib‐rituximab and Venetoclax (irv) Followed by Risk‐stratified R‐hypercvad/mtx in Young Patients With Untreated Mantle Cell Lymphoma—phase‐ii Window‐2 Trial
2023 · M. L. Wang, H. J. Lee, et al. · Hematological Oncology · 5
PDF
Phase 3 Study of Ibrutinib in Combination With Venetoclax in Patients With Relapsed/refractory Mantle Cell Lymphoma (mcl)
2017 · C.S. Tam, S. Rule, et al. · Hematological Oncology · 2
PDF
136 | Minimal Residual Disease With Bendamustine‐rituximab With or Without Acalabrutinib in Patients With Previously Untreated Mantle Cell Lymphoma: Results From the Echo Trial
2025 · P. L. Zinzani, S. Spurgeon, et al. · Hematological Oncology · 1
PDF
50 | FIXED‐DURATION OUTPATIENT SUBCUTANEOUS MOSUNETUZUMAB + POLATUZUMAB VEDOTIN SHOWS ROBUST EFFICACY IN A PHASE II STUDY OF RELAPSED/REFRACTORY POST‐BTKi MANTLE CELL LYMPHOMA
2025 · L. E. Budde, M. Kamdar, et al. · Hematological Oncology · 1
PDF
Pirtobrutinib in Covalent Btk‐inhibitor Pre‐treated Mantle Cell Lymphoma: Updated Results, Subgroup Analysis From Bruin With >3 Years Follow‐up From Start of Enrollment
2023 · C. Y. Cheah, N. N. Shah, et al. · Hematological Oncology · 1
PDF
P1117: Three-year Follow-up of Outcomes With Kte-x19 in Patients With Relapsed/refractory Mantle Cell Lymphoma in Zuma-2
2022 · M. L. Wang, J. Munoz, et al. · HemaSphere · 1
272 | Acalabrutinib in Combination With Rituximab Is Highly Effective Frontline Treatment for Older Patients With Mantle Cell Lymphoma
2025 · P. Jain, C. Y. Ok, et al. · Hematological Oncology
PDF
S209: Primary Results From the Phase 3 Shine Study of Ibrutinib in Combination With Bendamustine-rituximab (br) and R Maintenance as a First-line Treatment for Older Patients With Mantle-cell Lymphoma
2022 · M. L. Wang, W. Jurczak, et al. · HemaSphere
P1100: Bruin Mcl-321: a Phase 3 Open-label, Randomized Study of Pirtobrutinib Vs Investigator Choice of Btk Inhibitor in Patients With Previously Treated, Btk Inhibitor Naïve Mcl (trial in Progress)
2022 · T. A. Eyre, N. N. Shah, et al. · HemaSphere
P1101: Pirtobrutinib, a Highly Selective, Non-covalent (reversible) Btk Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 Bruin Study
2022 · T. A. Eyre, M. L. Wang, et al. · HemaSphere
First‐line Ibrutinib + Venetoclax Treatment for Mantle Cell Lymphoma in Older Patients or Those With Tp53 Mutation: a New Open‐label Arm of the Phase 3 Pcyc‐1143 Sympatico Study
2021 · W. Jurczak, C. Tam, et al. · Hematological Oncology
PDF
Percutaneous vertebroplasty and/or kyphoplasty is an effective and safe treatment for painful vertebral compression fractures in multiple myeloma (MM)
2006 · S. K. Thomas, M. L. Wang, et al. · Journal of Clinical Oncology
Works count: 18
Citation count: 281
H-index: 6
I10-index: 4
Year
Topic
Type